Robert Kimberly is a Rheumatology/Immunology physician affiliated with Regeneron. OpenAlex indexes 395 publications with 31,328 citations (h-index 97). By OpenAlex citation count, this profile ranks in the top 5% of Rheumatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1717 6th Ave S
Birmingham, AL 352331801
Telephone
800-822-8816Registry record last updated 1 Feb 2024.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20251 payment
- UCB, Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32.4%Folate Analog Metabolic Inhibitor22%Methotrexate100%Part D<11 patientsNonsteroidal Anti-inflammatory Drug10.4%Celecoxib100%Part D<11 patientsNervous system
19.8%Benzodiazepine13.2%Alprazolam54%Clonazepam46%Part D<11 patientsNonsteroidal Anti-inflammatory Drug6.6%Meloxicam100%Part D<11 patientsRespiratory
15.9%Opioid Agonist15.9%Hydrocodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
20 NIH research awards on record, funded 1996–2024 per NIH RePORTER. The latest:
- Host Factors in Response to Therapeutic Monoclonal Antibodies and Vaccination
University of Alabama at Birmingham
FY2024$445,487U01AI148108 - Center for Clinical and Translational Science
University of Alabama at Birmingham
FY2023$7,776,053UL1TR003096 - Host Factors in Response to Therapeutic Monoclonal Antibodies and Vaccination
University of Alabama at Birmingham
FY2023$445,190U01AI148108
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Vitti, MD
Regeneron
Thomas Uldrick, MD
Regeneron
Andrew Fontenot, MD
Regeneron
Mihaela Cristea, MD
Regeneron
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”